

doi: 10.4085/1062-6050-0322.23

**Title: Comparison of Step-Based Metrics Under Laboratory and Free-Living Conditions in Femoroacetabular Impingement Syndrome**

Naif Z. Alrashdi, PT, MSRS, PhD<sup>1</sup>; Elroy J. Aguiar, PhD<sup>2</sup>; Collin E. White<sup>3</sup>; Anna K. Saunders<sup>3</sup>; Amit M. Momaya, MD<sup>4</sup>; Benton A. Emblom, MD<sup>5,6</sup>; Michael K. Ryan, MD<sup>5,6</sup>; Robert W. Motl, PhD<sup>7</sup>; Matthew P. Ithurburn, PT, DPT, PhD<sup>6,8</sup>

1. Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Majmaah University, Al-Majmaah, 11952, Saudi Arabia (n.alrashedy@mu.edu.sa)
2. Department of Kinesiology, The University of Alabama, Tuscaloosa, AL, United States (ejaguiar@ua.edu)
3. Doctor of Physical Therapy Program, School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, United States (cwhite94@uab.edu and aks26@uab.edu)
4. Department of Orthopaedic Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States (amit.momaya@gmail.com)
5. The Hip Center at Andrews Sports Medicine and Orthopaedic Center, Birmingham, AL, United States (Benton.Emblom@andrewssm.com and mkryanmd@gmail.com)
6. American Sports Medicine Institute, Birmingham, AL, United States (Benton.Emblom@andrewssm.com; mkryanmd@gmail.com; matti@asmi.org)
7. Department of Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, United States (robmotl@uic.edu)
8. Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, United States (matti@asmi.org)

**Corresponding author:**

Naif Alrashdi, PT, MSRS, PhD; Assistant Professor, Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Science, Majmaah University, 11952, Riyadh, Saudi Arabia; [n.alrashedy@mu.edu.sa](mailto:n.alrashedy@mu.edu.sa)

**Conflict of Interests**

We have no conflict of interest to disclose.

## **Acknowledgement**

We thank Eric Mussell, MS for his assistance in the recruitment of participants with FAIS. We would also like to thank the Deanship of Scientific Research at Majmaah University for supporting this work under Project Number (R-2023-XXXX).

## **Funding Source**

This work was funded by the University of Alabama at Birmingham (UAB) School of Health Professions Junior Faculty Research Grant. Mr. Alrashdi's PhD studies were supported by the Saudi Arabian Cultural Mission.

## **Twitter Handles:**

Naif Alrashdi: @Naifz2ma

Elroy Aguiar: @ElroyAguiar

Amit Momaya: @AmitMomayaMD

Benton Emblom: @BentonEmblomMD

Michael Ryan: @MKRMD

Matthew Ithurburn: @MattIthurburnPT

Readers should keep in mind that the in-production articles posted in this section may undergo changes in the content and presentation before they appear in forthcoming issues. We recommend regular visits to the site to ensure access to the most current version of the article. Please contact the *JAT* office ([jat@slu.edu](mailto:jat@slu.edu)) with any questions.

Online First

# 1 Comparison of Step-Based Metrics Under Laboratory and Free-Living Conditions in 2 Femoroacetabular Impingement Syndrome

## 3 Abstract

4 **Context:** Femoroacetabular impingement syndrome (FAIS) causes pain and functional  
5 limitations. Little is known regarding walking characteristics, volume and intensity evaluated in  
6 laboratory and free-living conditions and whether these measures differ between those with FAIS  
7 and uninjured individuals.

8 **Objective:** To examine the differences in laboratory gait measures and free-living step-based  
9 metrics between individuals with FAIS and uninjured control participants.

10 **Design:** Comparative, cross-sectional study

11 **Patients or Other Participants:** We enrolled 25 participants with FAIS and 14 uninjured controls

12 **Main Outcome Measures:** We evaluated laboratory spatiotemporal gait measures (cadence,  
13 velocity, step length, stride length) during self-selected and fast walking speeds using an  
14 instrumented walkway. Participants then wore an accelerometer around the waist during waking  
15 hours for 7 consecutive days. Free-living step-based metrics included average daily steps, peak 1-  
16 and 30-minute cadence, and average daily time spent in walking cadence bands. We compared  
17 laboratory gait measures and step-based metrics between groups.

18 **Results:** The groups did not differ in laboratory spatiotemporal gait measures during both speeds  
19 (all  $p>0.05$ ). The FAIS group took fewer daily steps ( $5,346\pm 2,141$  vs.  $7,338\pm 2,787$  steps/day;  
20  $p=0.030$ ) and had a lower peak 1-minute ( $92.9\pm 23.9$  vs.  $119.6\pm 16.3$  steps/min;  $p<0.001$ ) and 30-  
21 minute cadences ( $60.9\pm 27.1$  vs.  $86.8\pm 22.4$  steps/min;  $p=0.003$ ) compared with uninjured controls,

22 respectively. The FAIS group also spent less time in slow ( $6.0\pm 3.6$  vs.  $10.3\pm 3.4$  min/day;  
23  $p=0.001$ ), medium ( $4.5\pm 4.2$  vs.  $8.9\pm 4.4$  min/day;  $p=0.005$ ), and brisk/moderate ( $4.5\pm 6.2$  vs.  
24  $12.2\pm 10.3$ ;  $p=0.020$ ) cadence bands compared with uninjured controls.

25 **Conclusions:** Considering only clinical/laboratory gait measures may not be representative of real-  
26 world walking-related PA behavior in individuals with FAIS.

27 **Key Words:**

28 Cadence, physical activity, FAIS, hip morphology

29 **Abstract Word Count:** 251

30 **Key Points:**

- 31 1. Individuals with FAIS took fewer daily steps, had a lower peak 1-minute and 30-minute  
32 walking cadence, and spent less time in faster rates of walking-related movement  
33 compared with controls.
- 34 2. Considering only clinical/laboratory gait measures may not be representative of real-  
35 world walking-related PA behavior in individuals with FAIS or in other musculoskeletal  
36 pain conditions.

## 37 INTRODUCTION

38 Femoroacetabular impingement syndrome (FAIS) is a pre-arthritis hip disorder  
39 characterized by bony morphology of the femoral head/neck (cam-type), the acetabulum (pincer-  
40 type), or in some cases, both (mixed-type).<sup>1</sup> This abnormal overgrowth of bone may lead to  
41 unbalanced force distribution in the hip joint that is thought to cause intra-articular injuries to the  
42 labrum and cartilage.<sup>2-6</sup> Individuals with FAIS often report hip pain,<sup>1,7,8</sup> limited hip-related  
43 function,<sup>9-11</sup> and poor quality-of-life,<sup>8,9,12</sup> and are at risk for developing early-onset hip  
44 osteoarthritis over time.<sup>13,14</sup> Importantly, regarding free-living function and activity, recent studies  
45 have reported that individuals with FAIS were less active than their peers,<sup>10,11,15,16</sup> and walked at  
46 slower speeds during laboratory-measured gait testing compared with healthy individuals.<sup>17</sup>

47 Across various patient populations, slow walking speed has been associated with disability,  
48 mortality, and other comorbidities (e.g., heart disease).<sup>18,19</sup> Cadence, or the number of steps an  
49 individual takes per minute, is a simple measure of gait function and physical activity that has wide  
50 appeal for researchers, clinicians, and the public.<sup>20-22</sup> Cadence can be measured using overground  
51 devices (e.g., gait mats) in controlled (laboratory) environments or using wearable technologies  
52 (e.g., fitness trackers and accelerometers) in uncontrolled (free-living) environments and provides  
53 a unique approach for determining an individual's physical activity and walking-related  
54 intensity.<sup>23</sup> Currently, little is known regarding walking characteristics, volume, and intensity  
55 evaluated in both laboratory and free-living conditions and whether these measures differ between  
56 those with FAIS and uninjured individuals. We are aware of only one study that has evaluated  
57 minute-by-minute time spent at varying stride frequencies (i.e., percent of time spent in no activity,  
58 low activity, medium activity, and high activity) between individuals with FAIS and healthy  
59 control participants.<sup>15</sup> That study reported no differences in the percentage of time spent across

60 stride frequencies between those with FAIS and healthy controls.<sup>15</sup> Further investigation is  
61 required to more comprehensively assess walking-related behavior using pragmatic approaches in  
62 a manner that considers both volume (e.g., steps/day) and stepping pattern/intensity (e.g., step-  
63 based metrics) under free-living conditions. Such findings could provide insight into how daily  
64 walking behavior is affected in those with FAIS; potentially providing critical markers of disease  
65 progression, recovery following treatment, and/or long-term joint health in this population.  
66 Additionally, clinical interventions could be developed to target free-living physical activity and  
67 walking behavior most affected in those with FAIS.

68 In this study, we compared laboratory gait measures (cadence, gait velocity, step length,  
69 and stride length) and free-living step-based metrics (daily steps; peak 1-minute and 30-minute  
70 cadence; and time spent in cadence bands) between individuals with FAIS and uninjured controls.  
71 We hypothesized that individuals with FAIS would demonstrate reduced spatiotemporal gait  
72 outcomes during laboratory-measured gait testing, take fewer daily steps, demonstrate lower peak  
73 1-minute and 30-minute walking cadence, and spend less time at higher paced/intensity walking  
74 than uninjured control participants.

## 76 **METHODS**

### 77 **Participants**

78 We enrolled two groups, individuals with FAIS and uninjured control participants.  
79 Individuals with a diagnosis of FAIS were recruited from the practice of two clinical collaborators  
80 (XXX; XXX) at XXX and XXX, respectively. Diagnosis of FAIS followed the Warwick  
81 Agreement (2016) consensus recommendations,<sup>1</sup> including a combination of the following

82 diagnostic criteria: 1) radiographic signs of impingement-related bony morphology (e.g., cam,  
83 pincer, or mixed); 2) positive clinical findings (e.g., painful hip range of motion or positive intra-  
84 articular provocation tests); and 3) reporting associated symptoms (groin/hip pain or stiffness).<sup>1</sup>  
85 We enrolled uninjured control participants who reported no history of groin/hip pain or major  
86 lower extremity injury/surgery (we included those with 2 or fewer lateral ankle sprains), and spine  
87 surgery from the local community via flyers and word of mouth. We performed a screening phone  
88 call with potential participants prior to enrollment, and we excluded both individuals with FAIS  
89 and potential control participants if they reported that they had been diagnosed with hip  
90 osteoarthritis, if diagnosed with osteopenia/osteoporosis, or if currently pregnant. Before enrolling  
91 in the study, we required all participants (FAIS and controls) to be actively engaged in a purposeful  
92 activity greater than 50 hours/year (or to have been prior to the onset of hip/groin pain for those  
93 with FAIS).<sup>24-26</sup> We obtained institutional review board approval for the study prior to initiation  
94 (IRB approval #XXXXX), and all participants provided written, informed consent prior to  
95 participating.

### 96 **Laboratory Assessments and Prior Activity Levels**

97 Standard demographic and anthropometric data were collected, including age, sex, and  
98 body mass index (BMI). Physical activity levels before enrolling in our study was evaluated in the  
99 FAIS and uninjured control participants using the International Physical Activity Questionnaire  
100 short form (IPAQ).<sup>27</sup> The IPAQ is a valid, reliable, and widely used tool for evaluating self-  
101 reported activity in the previous 7 days.<sup>27</sup> We measured spatiotemporal gait parameters in all  
102 participants using a GAITRite® PLATINUM PLUS CLASSIC walkway (GAITRite; Franklin,  
103 NJ). The GAITRite is a portable pressure-sensitive electronic walkway used to evaluate gait, and  
104 provides fast, clinically-relevant measures to identify gait abnormalities.<sup>28</sup> It has been used across

105 various patient populations, including in studies of those with total hip arthroplasty.<sup>29</sup> We assessed  
106 cadence (steps/minute), gait velocity (m/s), step length (cm), and stride length (cm) in all  
107 participants, during both a self-selected preferred and fastest (maximum) walking speed (2 trials  
108 at each speed). For the self-selected trials, we instructed participants to walk at a speed that they  
109 would use to purposefully go from one place to another. For the fastest walking speed, we  
110 instructed participants to walk as fast as possible without jogging or running. We used the software  
111 associated with the GAITRite to calculate average values (involved and uninvolved limbs for  
112 FAIS; right and left limbs for controls) over the 2 trials at both speeds for the aforementioned  
113 variables.

114

### 115 **Free-Living Step-based Metrics Assessment**

116 Following the laboratory visit, we provided all participants a waist-worn accelerometer  
117 (ActiGraph GT3X+, Pensacola, FL) to wear for 7 consecutive days on an elastic belt (above the  
118 non-painful hip for FAIS group; above the non-dominant hip for the control group<sup>10,11</sup>). We  
119 instructed participants to wear the accelerometer from when they awoke in the morning throughout  
120 the entire day, and to take it off only when sleeping or during water-based activities such as  
121 swimming or showering. We provided participants a daily log sheet to record the time they put the  
122 accelerometer on, the time they took it off, and any time during the day that the accelerometer was  
123 not worn. Accelerometers were initialized to collect continuous data at 100 Hz and summarized in  
124 in 1-minute epochs.<sup>30</sup> We downloaded and processed the accelerometry data using the Troiano  
125 wear-time algorithm<sup>31</sup>, and ActiGraph's proprietary step algorithm in the ActiLife software



126 (version 6.13.3). The final dataset included data from participants with valid wear time ( $\geq 8$  h of  
127 daily wear time for  $\geq 4$  valid days).<sup>32</sup>

128 Accelerometry data were further processed using a custom function in R (`step_metrics`;  
129 [https://github.com/jhmigueles/step\\_metrics](https://github.com/jhmigueles/step_metrics)) to produce three step-based metrics: 1) daily step  
130 counts (steps/day); 2) peak 1-minute cadence (steps/min); and 3) peak 30-minute cadence  
131 (steps/min). Peak 1-minute cadence summarizes an individual's highest minute of walking (best  
132 effort/pace in term of steps/min) within a day, averaged across all valid wear days. Peak 1-minute  
133 cadence values can be interpreted as an indicator of both functional capacity and behavioral  
134 decision to walk at higher/faster rates of movement.<sup>33-35</sup> Peak 30-minute cadence summarizes the  
135 highest 30 minutes (not necessarily consecutive) of activity within a day, averaged across all valid  
136 wear days. Peak 30-minute cadence reflects both the intensity and persistence of stepping behavior  
137 performed by individuals within and across days.<sup>34,36-38</sup> Additionally, the `step-metrics` function  
138 calculates time spent (minutes) within cadence bands, including non-movement (zero cadence),  
139 incidental movement (1-19 steps/min), sporadic movement (20-39 steps/min), purposeful  
140 movement (40-59 steps/min), slow walking (60-79 steps/min), medium walking (80-99 steps/min),  
141 brisk/moderate walking (100-119 steps/min), and faster walking ( $\geq 120$  steps/min),<sup>39,40</sup>, averaged  
142 across valid days.

143

## 144 **Statistical Analyses**

145 We compared demographic and anthropometric characteristics, IPAQ scores, laboratory  
146 spatiotemporal gait assessment (cadence, velocity, step length, stride length), step-based metrics  
147 (daily steps, peak 1-minute and 30-minute walking cadence), and time spent in various cadence

148 bands between the FAIS and control groups using independent sample *t*-tests (assumptions for *t*-  
149 tests were met). Cohen's *d* effect sizes were calculated and interpreted as: 0.2 small, 0.5 medium,  
150 0.8 large.<sup>41</sup> We used the Statistical Package for the Social Sciences (SPSS, V.27) for all statistical  
151 analyses, and a significance level was set a priori ( $\alpha < 0.05$ ).

152

## 153 RESULTS

154 Demographic and anthropometric data for the groups are shown in Table 1. There were no  
155 significant differences in age, sex distribution, body mass index (BMI), IPAQ scores, or  
156 accelerometer wear time between FAIS and uninjured control participants (Table 1; all  $p > 0.05$ ).  
157 Descriptive data for gait cadence, velocity, step length, and stride length during self-selected and  
158 fast walking speeds are shown for the groups in Table 2. Although the laboratory gait-related  
159 variables were not statistically different (all  $p > 0.05$ ), we did observe small to medium effect sizes  
160 ( $d = 0.2$  to  $0.7$ ). In particular, the FAIS group displayed lower cadence values during both the  
161 preferred and fast walking trials compared to controls.

162 There were significant differences in daily steps, peak 1-minute cadence, and 30-minute  
163 cadence between individuals with FAIS and uninjured control participants, with lower values  
164 observed for the FAIS group (Figures 1A, B, and C). Additionally, there were significant  
165 differences in average time (minutes) spent in slow walking, medium walking, and brisk/moderate  
166 walking between individuals with FAIS and uninjured control participants, with lower values  
167 observed for the FAIS group (Figures 2E, F, and G). No other significant group differences were  
168 found in the remaining cadence bands (all  $p$  values  $> 0.05$ ; Figures 2A, B, C, D, and H). Descriptive

169 data for daily steps, peak 1-minute and 30-minute cadence, and time spent in each cadence bands  
170 for both groups are presented in Table 3 (Supplemental).

171

## 172 **DISCUSSION**

173 Our main findings indicated that individuals with FAIS had significantly lower average  
174 daily steps, peak 1-minute and 30-minute walking cadence, and spent fewer minutes in slow,  
175 medium, and brisk walking paces/intensities compared with uninjured controls. In contrast,  
176 laboratory measured spatiotemporal parameters during self-selected and fast walking were not  
177 statistically different.

178 We hypothesized that there would be differences in spatiotemporal gait measures when  
179 comparing groups due to hip pain, limited hip range of motion, and/or patient reported symptoms  
180 that commonly associate with FAIS.<sup>1</sup> The FAIS group displayed a lower cadence during the  
181 preferred ( $p=0.077$ ,  $d=0.7$ , Table 2) and fast walking trials ( $p=0.239$ ,  $d=0.4$ , Table 2). However,  
182 these differences were not statistically significant despite a small to moderate between group effect  
183 sizes. Two previous studies have evaluated laboratory-measured gait speed, cadence, step length,  
184 and stride length in those with FAIS and uninjured control participants.<sup>17,42</sup> The first study reported  
185 that controls demonstrated significantly higher gait speed and cadence compared to FAIS  
186 individuals.<sup>17</sup> Notably, they reported gait parameters for the painful/involved limb within the  
187 FAIS group, whereas we report gait parameters based on the average value for involved and  
188 uninvolved limbs.<sup>17</sup> The second study reported no significant differences in laboratory gait  
189 measures between those with FAIS and controls, consistent with our laboratory gait-related  
190 findings.<sup>42</sup> In our study, we used a GaitRite walking mat to evaluate our laboratory gait measures,

191 whereas both of these other previous studies<sup>17,42</sup> used a three-dimensional motion capture system  
192 to evaluate laboratory gait measures. Differences in the accuracy of the measurement approach  
193 and the calculation of the specific laboratory gait-related measures, might explain, at least in part,  
194 the differences between our findings and that of previous studies.

195 When comparing free-living PA using step-based metrics, we observed significant differences  
196 in volume and peak metrics between the groups (Figures 1 and 2; see Supplement for detailed  
197 descriptive data). Specifically, average daily steps, peak 1-minute and peak 30-minute cadence  
198 were all higher in the healthy control group as compared to the FAIS group. Our findings regarding  
199 daily steps between individuals with FAIS and healthy controls were different from two previous  
200 published studies.<sup>11,15</sup> Whereas prior research found that those with FAIS demonstrate lower  
201 device-measured physical activity (general activity measured by volume and intensity<sup>10,11,15,16</sup>), two  
202 prior studies specifically evaluating step counts reported no significant difference between those  
203 with FAIS and healthy controls.<sup>11,15</sup> Regarding time spent in various cadence bands, uninjured  
204 controls and FAIS did not differ in time spent in non-movement, incidental movement, sporadic  
205 movement, and purposeful walking. Notably, however, the uninjured control group spent more time  
206 in slow walking, medium walking, and brisk walking compared with the FAIS group. This is in  
207 contrast to a previous study (n=74) that reported no significant differences in the percentage of  
208 time spent in various stride frequency bands in those with FAIS compared with healthy control  
209 participants.<sup>15</sup>

210 Several methodological aspects could explain the inconsistencies between our findings and  
211 previously published work regarding walking-related activity measures in those with FAIS in  
212 comparison to uninjured control participants. In our study, we recorded daily activity using an  
213 accelerometer over 7 days, including weekdays and weekends, where activity patterns might be

214 different.<sup>43</sup> Additionally, we used a waist-worn accelerometer placement that is more convenient  
215 for the participant and associated with better wear-time compliance.<sup>44</sup> Previous studies employed  
216 different methods to quantify activity.<sup>11,15</sup> For example, one study recorded daily activity only  
217 over 5 days and used a thigh-worn accelerometer, and did not specify whether weekday and/or  
218 weekend days were included.<sup>11</sup> Widely-accepted best practice is to measure physical activity over  
219 7 days to capture sufficient variability in estimating average daily activity,<sup>45,46</sup> and the average  
220 valid wear days were 6.2 and 6.6 days for the FAIS and control groups in our cohort, respectively.  
221 The other study that recorded daily activity for a 7-day period used a step-watch, an ankle-worn  
222 device.<sup>15</sup> Previous studies have reported differences between step-count estimate for the ankle-  
223 worn, thigh-worn, and waist-worn devices based on proximity to the foot.<sup>47</sup> In our study, we  
224 included participants (FAIS and controls) with similar demographic and anthropometric data (no  
225 significant differences between groups), however, both of the previously-published studies  
226 included participants (FAIS and controls) with a various range of age, sex, and BMI (FAIS were  
227 significantly different in demographic data in comparison to controls).<sup>11,15</sup> To that end, our results  
228 may have greater external validity, as the differences we observed in clinical and free-living gait  
229 parameters/physical activity between groups are less likely to be attributed to differences in  
230 demographic and anthropometric characteristics (no significant differences in  
231 demographic/anthropometric data between FAIS and controls), and more likely to be attributed to  
232 FAIS symptomology.

233 With respect to the pattern of physical activity accumulation (i.e., cadence bands), the control  
234 group spent approximately double the amount of time in slow and medium walking and triple  
235 amount of time in brisk walking intensities compared with FAIS group, with an observed large  
236 effect size between the groups (Table 3). However, the groups did not differ in the accumulation

237 of time in the lowest intensity cadence bands (i.e., non-movement, incidental movement, sporadic  
238 movement, and ourposful movement; Table 3). Overall, this may suggest that both groups spent  
239 similar time at the lowest walking intensity levels but spent differing amounts of time at higher  
240 intensities and faster rates of walking. The comparison of time spent in these cadence bands  
241 suggests that either individuals with FAIS lacked the capacity to walk at higher rates of movement  
242 or chose to limit the amount of time spent at faster rate of movement. Clinicians working with  
243 individuals with FAIS may consider using wearable devices to evaluate walking behavior in real-  
244 world settings that would enable them to better understand the impact of FAIS, the effectiveness  
245 of rehabilitation or medical interventions, and/or to develop or target behavioral interventions  
246 specific to free-living walking behavior in this patient population.

247 Our study has several strengths and limitations that should be considered when evaluating our  
248 findings. It is the first study to comprehensively examine step-based metrics including peak  
249 cadence and time spent at various cadence bands during free-living conditions between individuals  
250 with FAIS and demographically-similar uninjured control participants. Although our sample size  
251 was small, our comparative study design allowed us to evaluate differences between groups with  
252 similar demographic and anthropometrics characteristics. For our study's limitations, we  
253 processed our FAIS accelerometry-data using cut points developed from healthy individuals,  
254 which might underestimate intensity of activity in those with FAIS due to natural differences in  
255 energetic cost of movement between those with FAIS and healthy controls. There is a need for  
256 further research to develop FAIS-specific accelerometry cut points in order to accurately define  
257 activity intensity in those with FAIS. Furthermore, we could not assume causality due to the cross-  
258 sectional design, and there may be bi-directional and reverse causality in play, meaning that we do  
259 not know if pain/functional limitations lead to lower activity/intensity or lower activity/intensity

260 lead to pain/functional limitations. However, based on previous literature on patients with hip  
261 osteoarthritis, we know that hip-related pain and decreased function are often associated with low  
262 levels of activity.<sup>48</sup> Further, free-living physical activity, quantified herein using step-based  
263 metrics, may include non-step movement artifact. It is impossible to quantify the exact amount of  
264 measurement error related to this issue during free-living observation, however, we note that we  
265 collected and processed the accelerometer data per the manufacturer's recommendations and in  
266 general alignment with numerous other studies.<sup>46</sup> Minute level step data were computed and  
267 exported using ActiGraph's step algorithm, which has been validated both in laboratory controlled  
268 and free-living settings,<sup>49-51</sup> and is widely reported in the literature, including in national health  
269 surveillance such as the National Health and nutrition Examination Survey (NHANES;  
270 [https://wwwn.cdc.gov/nchs/nhanes/2005-2006/PAXRAW\\_D.htm](https://wwwn.cdc.gov/nchs/nhanes/2005-2006/PAXRAW_D.htm)). In the current study, we did  
271 not collect or control for pain scores in those with FAIS. Thus, it is possible that higher or lower  
272 pain intensity at the time of testing could have influenced functional performance and walking-  
273 related measures (previous research has shown us that higher pain is often associated with lower  
274 activity<sup>48</sup>). Lastly, due to our small sample size, some of our group comparisons may have been  
275 underpowered to detect relevant differences; particularly in laboratory-measured cadence values,  
276 which did not statistically differ between groups but demonstrated small to moderate effect sizes.

277 Future studies are needed to comprehensively evaluate PA metrics that reflect the volume  
278 (steps/day) and peak effort/intensity (peak 1-minute and 30-minute cadence) of ambulatory  
279 activity, as well as time spent at various cadence bands that reflect a range of movement from non-  
280 movement to faster rates of locomotion in larger sample of individuals with FAIS. Additionally,  
281 there is a need for studies to develop and validate disease-specific cut-points for quantifying PA  
282 intensity in patients with FAIS. As opposed to just testing walking-related measures in clinical

283 settings, clinicians should be encouraged to collect free-living physical activity data to examine  
284 effects of the clinical success of surgery alongside patient-reported outcomes in individuals with  
285 FAIS.

286

## 287 **CONCLUSION**

288 Individuals with FAIS took fewer daily steps, had a lower peak 1-minute and 30-minute  
289 walking cadence, and spent less time in faster rates of walking-related movement compared with  
290 uninjured control participants. Overall, clinical gait-related measures were generally similar  
291 between those with FAIS and uninjured controls when measured during laboratory testing, but  
292 those with FAIS demonstrated lower walking-related peak-effort/intensity during free-living  
293 measurement. Our findings support the use of wearable devices in patients with FAIS to examine  
294 how FAIS affects ambulation during free-living activity, and may be useful in identify deficits in  
295 gait parameters and step-based physical activity metrics that could be targeted through  
296 rehabilitation and/or behavioral interventions in this patient population.

Online First



297 **REFERENCES**

- 298 1. Griffin DR, Dickenson EJ, O'Donnell J, et al. The Warwick Agreement on  
299 femoroacetabular impingement syndrome (FAI syndrome): an international consensus  
300 statement. *Br J Sports Med.* 2016;50(19):1169-1176.
- 301 2. Agricola R, Waarsing JH, Thomas GE, et al. Cam impingement: defining the presence of  
302 a cam deformity by the alpha angle: data from the CHECK cohort and Chingford cohort.  
303 *Osteoarthritis Cartilage.* 2014;22(2):218-225.
- 304 3. Agricola R, Heijboer MP, Bierma-Zeinstra SMA, Verhaar JAN, Weinans H, Waarsing  
305 JH. Cam impingement causes osteoarthritis of the hip: a nationwide prospective cohort  
306 study (CHECK). *Annals of the Rheumatic Diseases.* 2013;72(6):918.
- 307 4. Ishoi L, Thorborg K, Kraemer O, Lund B, Mygind-Klavnsen B, Holmich P. Demographic  
308 and Radiographic Factors Associated With Intra-articular Hip Cartilage Injury: A Cross-  
309 sectional Study of 1511 Hip Arthroscopy Procedures. *Am J Sports Med.*  
310 2019:363546519861088.
- 311 5. Heerey J, Kemp J, Agricola R, et al. Cam morphology is associated with MRI-defined  
312 cartilage defects and labral tears: a case-control study of 237 young adult football players  
313 with and without hip and groin pain. *BMJ Open Sport Exerc Med.* 2021;7(4):e001199.
- 314 6. Alrashdi NZ, Brown-Taylor L, Bell MM, Ithurburn MP. Movement Patterns and their  
315 Associations with Pain, Function, and Hip Morphology in Individuals with  
316 Femoroacetabular Impingement Syndrome: A Scoping Review. *Physical therapy.* 2021.
- 317 7. Thorborg K, Kraemer O, Madsen AD, Holmich P. Patient-Reported Outcomes Within the  
318 First Year After Hip Arthroscopy and Rehabilitation for Femoroacetabular Impingement  
319 and/or Labral Injury: The Difference Between Getting Better and Getting Back to  
320 Normal. *Am J Sports Med.* 2018;46(11):2607-2614.
- 321 8. Rylander JH, Shu B, Andriacchi TP, Safran MR. Preoperative and postoperative sagittal  
322 plane hip kinematics in patients with femoroacetabular impingement during level  
323 walking. *Am J Sports Med.* 2011;39 Suppl:36s-42s.
- 324 9. Diamond LE, Dobson FL, Bennell KL, Wrigley TV, Hodges PW, Hinman RS. Physical  
325 impairments and activity limitations in people with femoroacetabular impingement: a  
326 systematic review. *Br J Sports Med.* 2015;49(4):230-242.

- 327 10. Kierkegaard S, Dalgas U, Lund B, Lipperts M, Soballe K, Mechlenburg I. Despite  
328 patient-reported outcomes improve, patients with femoroacetabular impingement  
329 syndrome do not increase their objectively measured sport and physical activity level 1  
330 year after hip arthroscopic surgery. Results from the HAFAI cohort. *Knee Surg Sports*  
331 *Traumatol Arthrosc.* 2019.
- 332 11. Reimer LCU, Kierkegaard S, Mechlenburg I, Jacobsen JS. Does Daily Physical Activity  
333 Differ Between Patients with Femoroacetabular Impingement Syndrome and Patients  
334 with Hip Dysplasia? A Cross-Sectional Study in 157 Patients and 60 Healthy Volunteers.  
335 *Int J Sports Phys Ther.* 2021;16(4):1084-1092.
- 336 12. Bagwell JJ, Snibbe J, Gerhardt M, Powers CM. Hip kinematics and kinetics in persons  
337 with and without cam femoroacetabular impingement during a deep squat task. *Clin*  
338 *Biomech (Bristol, Avon).* 2016;31:87-92.
- 339 13. Beck M, Kalhor M, Leunig M, Ganz R. Hip morphology influences the pattern of  
340 damage to the acetabular cartilage: femoroacetabular impingement as a cause of early  
341 osteoarthritis of the hip. *J Bone Joint Surg Br.* 2005;87(7):1012-1018.
- 342 14. Ganz R, Parvizi J, Beck M, Leunig M, Notzli H, Siebenrock KA. Femoroacetabular  
343 impingement: a cause for osteoarthritis of the hip. *Clin Orthop Relat Res.* 2003(417):112-  
344 120.
- 345 15. Harris-Hayes M, Steger-May K, Pashos G, Clohisy JC, Prather H. Stride activity level in  
346 young and middle-aged adults with hip disorders. *Physiother Theory Pract.*  
347 2012;28(5):333-343.
- 348 16. Alrashdi NZ, Motl RW, Samchok S, et al. Demographic and Clinical Correlates of  
349 Device-Measured Physical Activity Levels in Individuals with Femoroacetabular  
350 Impingement Syndrome. *Archives of Rehabilitation Research and Clinical Translation.*  
351 2023:100254.
- 352 17. Hunt MA, Guenther JR, Gilbert MK. Kinematic and kinetic differences during walking in  
353 patients with and without symptomatic femoroacetabular impingement. *Clin Biomech*  
354 *(Bristol, Avon).* 2013;28(5):519-523.
- 355 18. Batty GD, Shipley MJ, Kivimaki M, Marmot M, Davey Smith G. Walking pace, leisure  
356 time physical activity, and resting heart rate in relation to disease-specific mortality in

- 357 London: 40 years follow-up of the original Whitehall study. An update of our work with  
358 professor Jerry N. Morris (1910-2009). *Ann Epidemiol.* 2010;20(9):661-669.
- 359 19. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *Jama.*  
360 2011;305(1):50-58.
- 361 20. Bassett DR, Jr., Toth LP, LaMunion SR, Crouter SE. Step Counting: A Review of  
362 Measurement Considerations and Health-Related Applications. *Sports Med.*  
363 2017;47(7):1303-1315.
- 364 21. Evenson KR, Goto MM, Furberg RD. Systematic review of the validity and reliability of  
365 consumer-wearable activity trackers. *Int J Behav Nutr Phys Act.* 2015;12:159.
- 366 22. Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase  
367 physical activity and improve health: a systematic review. *Jama.* 2007;298(19):2296-  
368 2304.
- 369 23. Tudor-Locke C, Rowe DA. Using cadence to study free-living ambulatory behaviour.  
370 *Sports Med.* 2012;42(5):381-398.
- 371 24. Ithurburn MP, Paterno MV, Ford KR, Hewett TE, Schmitt LC. Young Athletes With  
372 Quadriceps Femoris Strength Asymmetry at Return to Sport After Anterior Cruciate  
373 Ligament Reconstruction Demonstrate Asymmetric Single-Leg Drop-Landing  
374 Mechanics. *Am J Sports Med.* 2015;43(11):2727-2737.
- 375 25. Ithurburn MP, Paljieg A, Thomas S, Hewett TE, Paterno MV, Schmitt LC. Strength and  
376 Function Across Maturational Levels in Young Athletes at the Time of Return to Sport  
377 After ACL Reconstruction. *Sports Health.* 2019;11(4):324-331.
- 378 26. Ithurburn MP, Paterno MV, Thomas S, et al. Clinical measures associated with knee  
379 function over two years in young athletes after ACL reconstruction. *The Knee.*  
380 2019;26(2):355-363.
- 381 27. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire:  
382 12-country reliability and validity. *Medicine and science in sports and exercise.*  
383 2003;35(8):1381-1395.
- 384 28. Papuga MO, Beck CA, Kates SL, Schwarz EM, Maloney MD. Validation of GAITRite  
385 and PROMIS as high-throughput physical function outcome measures following ACL  
386 reconstruction. *J Orthop Res.* 2014;32(6):793-801.

- 387 29. Casartelli NC, Item-Glatthorn JF, Bizzini M, Leunig M, Maffiuletti NA. Differences in  
388 gait characteristics between total hip, knee, and ankle arthroplasty patients: a six-month  
389 postoperative comparison. *BMC Musculoskeletal Disorders*. 2013;14(1):176.
- 390 30. Ezeugwu V, Klaren RE, E AH, Manns PT, Motl RW. Mobility disability and the pattern  
391 of accelerometer-derived sedentary and physical activity behaviors in people with  
392 multiple sclerosis. *Prev Med Rep*. 2015;2:241-246.
- 393 31. Troiano RP. Large-scale applications of accelerometers: new frontiers and new questions.  
394 *Medicine and science in sports and exercise*. 2007;39(9):1501.
- 395 32. Aadland E, Ylvisaker E. Reliability of the Actigraph GT3X+ Accelerometer in Adults  
396 under Free-Living Conditions. *PLoS One*. 2015;10(8):e0134606.
- 397 33. Tudor-Locke C, Han H, Aguiar EJ, et al. How fast is fast enough? Walking cadence  
398 (steps/min) as a practical estimate of intensity in adults: a narrative review. *Br J Sports*  
399 *Med*. 2018;52(12):776-788.
- 400 34. Tudor-Locke C, Brashear MM, Katzmarzyk PT, Johnson WD. Peak stepping cadence in  
401 free-living adults: 2005-2006 NHANES. *J Phys Act Health*. 2012;9(8):1125-1129.
- 402 35. Tudor-Locke C, Aguiar EJ. Toward Comprehensive Step-Based Physical Activity  
403 Guidelines: Are We Ready? *Kinesiology review (Champaign, Ill)*. 2019;8(1):25-31.
- 404 36. Aguiar EJ, Schuna JM, Jr., Barreira TV, et al. Normative Peak 30-Min Cadence (Steps  
405 per Minute) Values for Older Adults: NHANES 2005-2006. *Journal of aging and*  
406 *physical activity*. 2019;27(5):625-632.
- 407 37. Barreira TV, Katzmarzyk PT, Johnson WD, Tudor-Locke C. Cadence patterns and peak  
408 cadence in US children and adolescents: NHANES, 2005-2006. *Medicine and science in*  
409 *sports and exercise*. 2012;44(9):1721-1727.
- 410 38. Barreira TV, Schuna JM, Jr., Mire EF, et al. Normative steps/day and peak cadence  
411 values for united states children and adolescents: National Health and Nutrition  
412 Examination Survey 2005-2006. *J Pediatr*. 2015;166(1):139-143.
- 413 39. Rowlands AV, Stone MR, Eston RG. Influence of speed and step frequency during  
414 walking and running on motion sensor output. *Medicine and science in sports and*  
415 *exercise*. 2007;39(4):716-727.
- 416 40. Tudor-Locke C, Camhi SM, Leonardi C, et al. Patterns of adult stepping cadence in the  
417 2005-2006 NHANES. *Prev Med*. 2011;53(3):178-181.

- 418 41. Cohen J. *Statistical power analysis for the behavioral sciences*. 2nd ed. ed. Hillsdale, N.J:  
419 L. Erlbaum Associates; 1988.
- 420 42. Diamond LE, Wrigley TV, Bennell KL, Hinman RS, O'Donnell J, Hodges PW. Hip joint  
421 biomechanics during gait in people with and without symptomatic femoroacetabular  
422 impingement. *Gait Posture*. 2016;43:198-203.
- 423 43. To QG, Stanton R, Schoeppe S, Doering T, Vandelanotte C. Differences in physical  
424 activity between weekdays and weekend days among U.S. children and adults: Cross-  
425 sectional analysis of NHANES 2011-2014 data. *Prev Med Rep*. 2022;28:101892.
- 426 44. Cleland I, Kikhia B, Nugent C, et al. Optimal placement of accelerometers for the  
427 detection of everyday activities. *Sensors (Basel)*. 2013;13(7):9183-9200.
- 428 45. Migueles JH, Cadenas-Sanchez C, Ekelund U, et al. Accelerometer Data Collection and  
429 Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic  
430 Review and Practical Considerations. *Sports Med*. 2017;47(9):1821-1845.
- 431 46. Tudor-Locke C, Camhi SM, Troiano RP. A catalog of rules, variables, and definitions  
432 applied to accelerometer data in the National Health and Nutrition Examination Survey,  
433 2003-2006. *Prev Chronic Dis*. 2012;9:E113.
- 434 47. Mora-Gonzalez J, Gould ZR, Moore CC, et al. A catalog of validity indices for step  
435 counting wearable technologies during treadmill walking: the CADENCE-adults study.  
436 *Int J Behav Nutr Phys Act*. 2022;19(1):117.
- 437 48. Leichtenberg CS, van Tol FR, Gademan MGJ, et al. Are pain, functional limitations and  
438 quality of life associated with objectively measured physical activity in patients with end-  
439 stage osteoarthritis of the hip or knee? *The Knee*. 2021;29:78-85.
- 440 49. Toth LP, Park S, Pittman WL, et al. Validity of Activity Tracker Step Counts during  
441 Walking, Running, and Activities of Daily Living. *Translational Journal of the ACSM*.  
442 2018;3:52-59.
- 443 50. Park S, Marcotte RT, Toth LP, et al. Free-living validation and harmonization of 10  
444 wearable step count monitors. *Translational Journal of the American College of Sports  
445 Medicine*. 2021;6(4):e000172.
- 446 51. Toth LP, Park S, Springer CM, Feyerabend MD, Steeves JA, Bassett DR. Video-  
447 Recorded Validation of Wearable Step Counters under Free-living Conditions. *Medicine  
448 and science in sports and exercise*. 2018;50(6):1315-1322.

450 **Figures Legends**

451 **Figure 1:** Group Comparisons of Daily Steps (A), Peak 1-minute (B), and 30-minute Cadence

452 (C)

453 **Figure 2:** Group Comparisons of Average Time Spent in Cadence Bands

Online First

**Table 1: Characteristics of the Sample at the Testing Visit**

	<b>FAIS Group (n=25)</b>	<b>Control Group (n=14)</b>	<b><i>p-value</i><sup>^</sup></b>
<b>Age*</b> , years (range)	31.0 ± 9.2 (18.8-46.0)	28.1 ± 9.1 (20.4-50.4)	0.341
<b>Sex, n (%)</b>			0.792
Female	15 (60%)	9 (64%)	
Male	10 (40%)	5 (36%)	
<b>Height*</b> , cm	173.0 ± 13.1	170.2 ± 6.8	0.394
<b>Weight*</b> , kg	78.7 ± 21.7	76.1 ± 10.6	0.624
<b>Body Mass Index*</b> , kg/m <sup>2</sup>	26.1 ± 4.7	26.3 ± 3.4	0.899
<b>Accelerometer Wear Time*</b> mean daily minutes	824.3 ± 71.5	836.7 ± 57.3	0.581
<b>FAIS Subtype, n (%)</b>			
Cam	13 (52%)	--	--
Pincer	4 (16%)		
Combined	8 (32%)		
<b>Symptom Duration*</b> , years	4.7 ± 7.1	--	--
<b>IPAQ Scores:</b>			
<b>Average Time Spent in Vigorous Activity,</b>	<b>38.8 ± 61.4</b>	<b>34.1 ± 25.0</b>	<b>0.747</b>

<b>minutes</b>			
<b>Average Time Spent in Moderate Activity, minutes</b>	<b>43.9 ± 85.0</b>	<b>16.4 ± 16.3</b>	<b>0.112</b>
<b>Average Time Spent in Walking, minutes</b>	<b>147.2 ± 172.0</b>	<b>67.9 ± 113.8</b>	<b>0.067</b>

Notes: \*Data are reported as mean ± standard deviation (range) or n (%). ^P-values from independent two-samples t-tests for continuous data or Pearson chi-square tests for categorical data. FAIS, femoroacetabular impingement syndrome; kg, kilograms; cm, centimeters; m, meter. **IPAQ, international physical activity questionnaire.**

Online First



**Table 2: Comparisons of Laboratory Gait Parameters During Self-Selected and Fast Walking Speeds**

		<b>FAIS Group (n=20)</b>	<b>Control Group (n=12)</b>	<i>p-value</i>	<i>Effect Size (Cohen's d)</i>
<b>Self-Selected speed</b>	Cadence (steps/min)	113.6 ± 18.4	124.8 ± 15.5	0.077	0.7
	Velocity (m/s)	1.5 ± 0.5	1.6 ± 0.4	0.402	0.3
	Step Length (cm)	76.3 ± 11.9	76.9 ± 9.9	0.878	0.1
	Stride Length (cm)	152.8 ± 24.0	154.3 ± 9.7	0.858	0.1
<b>Fast-Walking Speed</b>	Cadence (steps/min)	131.2 ± 17.5	138.8 ± 16.9	0.239	0.4
	Velocity (m/s)	1.9 ± 0.4	2.0 ± 0.41	0.625	0.2
	Step Length (cm)	86.5 ± 10.9	84.5 ± 10.2	0.594	0.2
	Stride Length (cm)	173.7 ± 21.9	169.4 ± 20.5	0.582	0.2

Notes: All data are reported as mean ± standard deviation. P-value was obtained using independent two samples t-tests. FAIS, femoroacetabular impingement syndrome; min; minute, cm; centimeter.


**Table 3: Comparison of Step-Based Metrics and Time Spent within Different Cadence Bands between FAIS and Uninjured Controls**

Outcome	FAIS (n=25)	Uninjured Controls (n=14)	p-value	Effect Size (Cohen's d)
Average wear valid days (days)	6.2 ± 1.0	6.6 ± 0.7	0.170	0.4
Daily Steps	5,346 ± 2,141	7,338 ± 2,787	0.030*	0.8
Peak 1-Minute Cadence (steps)	92.9 ± 23.9	119.6 ± 16.3	<0.001*	1.3
Peak 30-Minute Cadence (steps)	60.9 ± 27.1	86.8 ± 22.4	0.003*	1.0
Time Spent (mins/day) at non-movement (zero cadence/min)	1,079.0 ± 59.8	1,070.5 ± 97.3	0.769	0.1
Time Spent (mins/day) at incidental movement (1-19 steps/min)	273.7 ± 50.7	253.6 ± 74.4	0.378	0.3
Time Spent (mins/day) at sporadic movement (20-39 steps/min)	45.4 ± 19.9	46.0 ± 18.9	0.926	0.03
Time Spent (mins/day) at purposeful movement (40-59 steps/min)	15.6 ± 9.6	19.6 ± 6.5	0.134	0.5
Time Spent (mins/day) at slow walking (60-79 steps/min)	6.0 ± 3.6	10.3 ± 3.4	<0.001*	1.2
Time Spent (mins/day) at medium walking				


(80-99 steps/min)	4.5 ± 4.2	8.9 ± 4.4	0.005*	1.0
Time Spent (mins/day) at brisk/moderate waking (100-119 steps/min)	4.5 ± 6.2	12.2 ± 10.3	0.020*	0.9
Time Spent (mins/day) at faster walking (+120 steps/min)	4.0 ± 8.5	5.7 ± 5.9	0.461	0.2

Notes: Data are reported as mean ± standard deviation. P-values were obtained using independent two samples t-tests. \* denotes significant difference between groups ( $p < 0.05$ ). FAIS, femoroacetabular impingement syndrome; min; minute

Online First



**Figure 1: Group Comparisons of Daily Steps (A), Peak 1-minute (B), and 30-minute Cadence (C)**



**Figure 2: Group Comparisons of average time spent in Cadence Bands**